II. Precautions
-
Aspirin is lifelong therapy for known cardiovascular disease (secondary prevention)
- Should not be interrupted for surgery following stroke, Acute Coronary Syndrome, or coronary revascularization
- This is regardless of time since vascular event or procedure
- See risks below regarding stopping Aspirin in the perioperative period
-
Clopidogrel (Plavix) in combination with Aspirin
- Should be continued at least until endothelialization of the stent or lesion can reasonably be expected
- For Drug-eluting Stents this duration is for a minimum of 1 year
- May extend 2-3 years especially in high risk patients (see below)
III. Physiology: Antiplatelet agents and bleeding risk
IV. Physiology: Stent and coronary lesion endothelialization
- Stents and coronary lesions act as unstable Plaque until fully covered by a cellular layer
- Bare metal stents are completely covered by Smooth Muscle within 6 weeks and by endothelium within 3 months
- Drug eluting stents require 1-3 years for endothelialization
- Stent thrombosis is a catastrophic event (up to 45% mortality)
V. Physiology: Antiplatelet agent cessation and thrombosis risk
- Aspirin cessation: 3.1 Odds Ratio of cardiac complication (peak at 10 days)
-
Aspirin cessation after coronary stent: 90 Odds Ratio
- Even 2 years after Drug-eluting Stent placement, Aspirin cessation may result in stent stenosis
- Clopidogrel cessation after drug eluting stent: Up to 57 Odds Ratio in first 18 months
- Risk of stent closure increases in the perioperative period due to increased Platelet aggregation activity
VI. Evaluation: Surgical Bleeding Risk
- See Perioperative Anticoagulation for complete list
- Low surgical bleeding risk (transfusion not required)
- Minor otolaryngology surgery
- Minor orthopedic surgery
- Endoscopy without biopsy
- Anterior chamber eye surgery
- Dentistry
- Intermediate surgical bleeding risk (transfusion may be required)
- Visceral surgery
- Vascular surgery
- Major otolaryngology surgery
- Major orthopedic surgery
- Endoscopy with biopsy
- High surgical bleeding risk (transfusion required)
- Cardiac surgery
- Surgery with massive bleeding (e.g. transurethral Prostatectomy)
- Surgery in a closed space
- Intracranial surgery
- Major spinal surgery
- Bone Intramedullary canal procedures
- Posterior eye chamber
VII. Evaluation: Cardiac Risk for perioperative events in known coronary disease
- Low Cardiac Risk
- Bare metal stents, Angioplasty, or CABG >3 months prior
- Acute Coronary Syndrome >6 months prior
- Drug-eluting Stent >12 months prior
- Intermediate Cardiac Risk
- Bare metal stents, Angioplasty, or CABG 6 weeks to 3 months prior
- Acute Coronary Syndrome 6 weeks to 6 months prior
- High Risk Drug-eluting Stent >12 months prior
- Stent in dominant, proximal, ostial or bifurcated position or
- High risk patient with advanced age, Diabetes Mellitus, low ejection fraction or Renal Failure
- High Cardiac Risk
- Bare metal stents, Angioplasty, or CABG, Acute Coronary Syndrome <6 weeks prior (<3 months if complications)
- Drug-eluting Stent <12 months prior (longer if high risk drug eluting stent)
VIII. Protocol: ACC/AHA Guidelines 2016-2022
- No known cardiovascular disease (primary prevention)
- If significant risk of cardiovascular event (Revised Cardiac Risk Index)
- Follow guidelines for secondary prevention as below
- Stop Aspirin 7-10 days prior to surgery
- Restarting Aspirin
- If significant risk of cardiovascular event (Revised Cardiac Risk Index)
- Known cardiovascular disease (secondary prevention)
- Aspirin
- Continue without stopping through perioperative period
- Only stop Aspirin if high risk of bleeding (see above)
- Platelet ADP Receptor Antagonist (e.g. Clopidogrel, Dual Antiplatelet Therapy)
- Continue Aspirin perioperatively if possible while off Platelet ADP Receptor Antagonist
- Elective surgery
- Postpone surgery for 30 days after bare metal stent, 6 months after Drug-eluting Stent
- Postpone surgery for 1 year after Acute Coronary Syndrome
- Hold Platelet ADP Receptor Antagonist perioperatively
- Important surgery to be done as soon as possible (risk of delay)
- Postpone surgery for >3 months after Drug-eluting Stent (or use dual antiplatelets periop)
- Postpone surgery for 1 year after Acute Coronary Syndrome (or use dual antiplatelets periop)
- Hold Platelet ADP Receptor Antagonist perioperatively
- Urgent or emergent surgery
- Continue dual antiplatelet agents unless major bleeding risk (e.g. active bleeding, intracranial surgery)
- Aspirin
- Timing of stopping and starting specific Platelet ADP Receptor Antagonists
- Stop Prasugrel (Effient) 7 to 10 days before surgery
- Stop Clopidogrel (Plavix) 5 days before surgery
- Stop Ticagrelor (Brilinta) 3 to 5 days before surgery
- All Platelet ADP Receptor Antagonists may be restarted 24 hours after surgery (assuming Hemostasis control)
- References
IX. References
- (2009) Anesthesiology 110(1):22-3 [PubMed]
- Chassot (2007) Br J Anaesth 99(3):316-28 [PubMed]
- Chassot (2010) Am Fam Physician 82(12): 1484-9 [PubMed]
- Douketis (2008) Chest 133(6):299S-339S [PubMed]
- Douketis (2022) Chest 162(5):e207-43 +PMID: 35964704 [PubMed]
- Mikhail (2017) Am Fam Physician 95(10): 645-50 [PubMed]